CLIP1 Antibody

What is CLIP1 and what are its primary biological functions?

CLIP1 is a member of microtubule (MT) plus-end tracking proteins (+TIPs) that specifically associates with the ends of growing microtubules. It functions primarily to regulate microtubule dynamic behavior and plays important roles in:

• MT-mediated transport over the length of axons and dendrites

• Neuronal development and polarization

• Kinetochore-MT attachments during mitosis

• Acting as an anti-catastrophe factor in mammalian cells during interphase

• Controlling dendrite morphology in neurons

• Spermatogenesis

• Linking the actin cytoskeleton to microtubules during cell migration

CLIP1 has recently been implicated in autosomal recessive intellectual disability (ARID), with research showing that loss-of-function mutations can cause cognitive impairment . Additionally, CLIP1 has been found to modulate inflammatory responses in liver transplantation through interaction with the TFPI2/TIRAP signaling pathway .

What molecular characteristics should researchers be aware of when working with CLIP1 protein?

Researchers should note the following key molecular characteristics:

• Full protein size: CLIP1 consists of 1438 amino acids with a calculated molecular weight of 162 kDa

• Observed molecular weight: CLIP1 typically appears at 160-170 kDa on Western blots, with some antibodies also detecting a 135 kDa band

• Protein domains: CLIP1 contains N-terminal CAP-Gly domains that bind microtubules, central coiled-coil regions, and C-terminal metal-binding motifs that are essential for its functions

• UNIPROT ID: P30622

• Gene ID (NCBI): 6249

These characteristics are important for validating antibody specificity and interpreting experimental results when working with CLIP1.

How can researchers distinguish between CLIP1 and its relative CLIP2 in experimental systems?

Distinguishing between these related proteins requires careful antibody selection and experimental design:

• Antibody selection: Use antibodies specifically targeting unique regions of CLIP1. For instance, antibodies against the C-terminus (such as Ab 2360) are specific to CLIP1, while some antibodies (like Ab 2221) recognize the N-terminus of both CLIP1 and CLIP2

• Molecular weight distinction: While both appear at the microtubule plus-ends, they can be distinguished by molecular weight (CLIP1: 160-170 kDa)

• Control experiments: Include CLIP1-knockout or knockdown samples to confirm antibody specificity

• Immunofluorescence patterns: In cases where both proteins are present, CLIP1-specific antibodies (against C-terminus) will show MT plus-end staining only in cells expressing CLIP1, while antibodies that recognize both proteins will show staining in both CLIP1-expressing and CLIP1-deficient cells

This distinction is particularly important in neuronal studies, as both CLIP1 and CLIP2 appear to regulate neuronal polarization through microtubules and growth cone dynamics .

What are the validated applications and optimal dilutions for CLIP1 antibodies in different experimental techniques?

Based on validated research protocols, the following applications and dilutions are recommended when working with CLIP1 antibodies:

Positive WB detection has been confirmed in HeLa cells, HEK-293 cells, MCF-7 cells, mouse kidney tissue, rat kidney tissue, and U-937 cells. Positive IP has been detected in HeLa cells, and positive IF/ICC has been detected in HeLa cells .

It is crucial to titrate the antibody in each testing system to obtain optimal results, as the optimal concentration may be sample-dependent .

What is the detailed protocol for Western blot analysis of CLIP1 protein?

For optimal Western blot detection of CLIP1:

• Sample preparation:

  • Extract whole-cell lysates using Tris-Triton lysis buffer supplemented with protease and phosphatase inhibitors

  • Include control samples with known CLIP1 status (positive and negative controls)

• Gel electrophoresis:

  • Use 6% SDS-polyacrylamide gels due to the large size of CLIP1 (160-170 kDa)

  • Load adequate protein (typically 20-50 μg total protein per lane)

• Transfer:

  • Transfer to PVDF membrane

  • Use overnight transfer at low voltage for large proteins or semi-dry transfer systems optimized for large proteins

• Antibody incubation:

  • Block with appropriate blocking buffer (typically 5% non-fat milk or BSA)

  • Incubate with primary CLIP1 antibody at dilutions between 1:1000-1:6000

  • For detecting specific domains, select appropriate antibodies (e.g., Ab 2360 for C-terminus or Ab 2221 for N-terminus)

  • Use beta-Actin (1:10,000 dilution) as a loading control

• Detection:

  • Use chemiluminescence detection systems such as BM Chemiluminescence Western Blotting Kit

  • Expect bands at approximately 160-170 kDa (full-length CLIP1) and possibly 135 kDa

This protocol has been successfully employed in research examining CLIP1 expression in patient-derived cell lines and control samples .

How should researchers prepare samples for CLIP1 immunofluorescence studies?

For optimal immunofluorescence detection of CLIP1:

• Cell preparation:

  • Seed cells onto glass coverslips and allow adequate growth time

  • For primary cells, coat coverslips with appropriate substrate (poly-L-lysine, collagen, etc.)

• Fixation and permeabilization:

  • Fix cells (typically with 4% paraformaldehyde)

  • Permeabilize with 0.1-0.5% Triton X-100

  • Block with appropriate blocking buffer (typically containing BSA and normal serum)

• Antibody incubation:

  • Incubate with primary CLIP1 antibody at dilutions between 1:50-1:500

  • Co-stain with microtubule markers (e.g., alpha-tubulin) to visualize MT structures

  • For domain-specific detection, select appropriate antibodies (C-terminus-specific or N-terminus-specific)

• Imaging:

  • Acquire images using confocal microscopy for optimal resolution of MT plus-end structures

  • When properly performed, CLIP1 staining appears as distinct comet-like structures at the growing ends of microtubules

This protocol has been successfully used to distinguish between CLIP1 and CLIP2 localization in fibroblast cell lines from normal individuals and patients with CLIP1 mutations .

What RNA analysis methods can be used to complement CLIP1 protein studies?

RNA analysis provides important complementary data to protein studies of CLIP1. The following methodologies have been validated:

• RNA extraction:

  • Extract total cellular RNA from cell lines using RNeasy Mini Kit or comparable methods

  • Assess RNA quality and quantity before proceeding

• cDNA synthesis:

  • Use 1 μg of total RNA for first-strand cDNA synthesis

  • QuantiTect Rev. Transcription Kit or similar reverse transcription systems are suitable

• RT-PCR analysis:

  • Design primers specific to CLIP1 transcript variants

  • Place primers across exon-exon junctions to avoid genomic DNA amplification

  • Include housekeeping gene controls (e.g., GAPDH)

• Quantitative RT-PCR:

  • For precise quantification of CLIP1 transcript levels

  • Useful for comparing expression between experimental conditions

  • Has been successfully used to detect reduced levels of mutated CLIP1 transcripts in patient cells (showing only 25-30% of normal CLIP1 transcript levels)

These methodologies provide valuable information about CLIP1 transcripts that can explain protein-level observations, particularly in cases of nonsense-mediated decay of mutant transcripts .

Why might researchers observe multiple bands or unexpected molecular weights when using CLIP1 antibodies in Western blot?

Multiple or unexpected bands with CLIP1 antibodies may occur for several biological and technical reasons:

• Multiple CLIP1 isoforms:

  • CLIP1 is observed at both 160-170 kDa (full-length) and sometimes at 135 kDa, which may represent alternative splice variants or post-translationally modified forms

  • Domain-specific antibodies may detect different subsets of isoforms

• Proteolytic degradation:

  • Inadequate protease inhibition during sample preparation can cause fragmentation

  • Ensure fresh protease inhibitors are included in all lysis buffers

• Post-translational modifications:

  • Phosphorylation, ubiquitination, or other modifications can alter mobility

  • CLIP1 has been shown to undergo ubiquitination in some contexts, which may produce higher molecular weight bands

• Cross-reactivity:

  • Antibodies targeting the N-terminus may detect both CLIP1 and the related CLIP2 protein

  • Confirm specificity using knockout/knockdown controls or domain-specific antibodies

• Verification strategy:

  • Use multiple antibodies targeting different epitopes (e.g., N-terminal vs. C-terminal)

  • Include positive and negative control samples

  • For suspected truncated variants, compare results using domain-specific antibodies (e.g., Ab 2360 for C-terminus and Ab 2221 for N-terminus)

Understanding these factors can help researchers properly interpret western blot results and validate their findings.

What are the critical validation steps to confirm CLIP1 antibody specificity in experimental systems?

• Control samples:

  • Positive controls: Cell lines with confirmed CLIP1 expression (e.g., HeLa, HEK-293, MCF-7 cells)

  • Negative controls: CLIP1 knockout or knockdown cells

  • Heterozygous samples: When available, samples from heterozygous carriers can provide intermediate expression levels

• Multiple detection methods:

  • Compare results across techniques (WB, IF, IP) to ensure consistent findings

  • Use multiple antibodies targeting different epitopes

  • For domain-specific questions, use antibodies targeting distinct regions (N- versus C-terminus)

• Specificity controls:

  • Preabsorption with immunizing peptide/protein

  • Sequential probing with different CLIP1 antibodies

  • Side-by-side comparison with CLIP2-specific antibodies to rule out cross-reactivity

• Functional validation:

  • Confirm microtubule plus-end localization in immunofluorescence

  • Verify expected molecular weight on Western blots

  • For mutant studies, confirm the presence/absence of domains using domain-specific antibodies

Implementation of these validation steps has been successfully used to confirm the specificity of CLIP1 antibodies in studies of autosomal recessive intellectual disability .

How can researchers optimize CLIP1 detection in immunofluorescence studies?

For optimal visualization of CLIP1 at microtubule plus-ends:

• Cell fixation optimization:

  • Test multiple fixation protocols as some may better preserve microtubule structures

  • Methanol fixation often preserves microtubule cytoskeleton but may affect some epitopes

  • Paraformaldehyde (4%) followed by mild permeabilization often provides good results

• Antibody concentration:

  • Titrate antibody concentration between 1:50-1:500 for optimal signal-to-noise ratio

  • Run parallel samples with different dilutions to determine optimal conditions

• Colocalization markers:

  • Co-stain with microtubule markers (α-tubulin) to verify plus-end localization

  • Consider co-staining with other +TIP proteins (EB1, EB3) as positive controls

• Imaging parameters:

  • Use confocal microscopy for optimal resolution of plus-end structures

  • Acquire z-stacks to capture the full 3D organization of microtubules

  • For dynamic studies, consider live-cell imaging with fluorescently tagged CLIP1

• Controls for specificity:

  • Include CLIP1-deficient cells as negative controls

  • Use both N-terminal and C-terminal antibodies to confirm staining patterns

  • Compare with CLIP2-specific antibodies to distinguish between these related proteins

These optimization strategies have been successfully employed to visualize CLIP1 at microtubule plus-ends in fibroblast cells, confirming the absence of CLIP1 in patient-derived cells with CLIP1 mutations .

How can CLIP1 antibodies be utilized to investigate microtubule dynamics in neuronal development?

CLIP1 antibodies offer powerful tools for studying neuronal development through these advanced approaches:

• Developmental expression profiling:

  • Track CLIP1 expression levels during different stages of neuronal development

  • Compare CLIP1 localization in developing versus mature neurons

  • Evaluate co-expression with CLIP2, which together with CLIP1 regulates neuronal polarization

• Growth cone dynamics analysis:

  • Use immunofluorescence to visualize CLIP1 localization at growth cone microtubules

  • Combine with live imaging to correlate CLIP1 dynamics with growth cone behavior

  • Investigate CLIP1's role in growth cone steering and axon pathfinding

• Dendritic morphology studies:

  • Apply CLIP1 antibodies to study its role in dendritic development

  • Combine with morphometric analysis to quantify dendritic complexity

  • CLIP1 together with IQGAP1 has been shown to control dendrite morphology in rat neurons

• Domain-specific functions:

  • Use domain-specific antibodies to dissect the roles of different CLIP1 regions

  • Compare C-terminal versus N-terminal antibody staining to understand domain-specific functions

  • Examine how mutations affecting specific domains influence neuronal polarization and growth

These approaches can provide crucial insights into the mechanisms of neuronal development and the role of CLIP1 in neurodevelopmental disorders such as intellectual disability .

What methodologies can researchers employ to study CLIP1's role in intellectual disability?

Researchers investigating CLIP1's connection to intellectual disability can implement these advanced methodologies:

• Patient-derived cell studies:

  • Establish lymphoblastoid and fibroblast cell lines from patients with CLIP1 mutations

  • Compare CLIP1 expression and localization between patient and control cells

  • Assess microtubule organization and dynamics in patient-derived cells

• Transcript analysis:

  • Perform RT-PCR and quantitative RT-PCR to assess CLIP1 transcript levels

  • Investigate nonsense-mediated decay of mutant transcripts

  • Design primers across exon-exon junctions to specifically detect transcript variants

• Protein functional analysis:

  • Use domain-specific antibodies to detect truncated or modified CLIP1 proteins

  • Perform immunofluorescence to assess microtubule plus-end tracking

  • Compare MT plus-end staining patterns between normal and patient-derived cells

• Rescue experiments:

  • Reintroduce wild-type CLIP1 into patient-derived cells

  • Assess whether this rescues cellular phenotypes

  • Compare different CLIP1 domains for their ability to rescue function

• Interaction partner analysis:

  • Investigate CLIP1 interactions with known partners (e.g., IQGAP1, dynactin)

  • Determine whether mutations disrupt these interactions

  • CLIP1's second zinc knuckle in the C-terminal domain interacts with dynactin subunit 1 (DCTN1)

These methodologies have successfully revealed that CLIP1 loss-of-function mutations can lead to autosomal recessive intellectual disability, with complete absence of CLIP1 protein in patient-derived cells .

How can researchers investigate the role of CLIP1 in inflammatory pathways and liver transplantation?

Recent research has identified CLIP1's involvement in inflammatory pathways, particularly in the context of liver transplantation. Researchers can explore this using:

• Ischemia-reperfusion injury models:

  • Develop rat models of fatty liver ischemia-reperfusion injury (IRI)

  • Compare standard cold storage with hypothermic oxygenated perfusion (HOPE)

  • Assess CLIP1 expression and localization before and after IRI

• Signaling pathway analysis:

  • Investigate CLIP1's interaction with TFPI2 (tissue factor pathway inhibitor-2)

  • Examine how CLIP1 affects TIRAP (Toll/interleukin-1 receptor domain-containing adapter protein) ubiquitination

  • Analyze TLR4/NF-κB pathway activation using phospho-specific antibodies for p65 and IκBα

• Protein-protein interaction studies:

  • Perform co-immunoprecipitation to detect CLIP1-TFPI2 interactions

  • Investigate binding between R24 of the KD1 domain of TFPI2 with CLIP1

  • Examine how these interactions affect downstream signaling pathways

• Ubiquitination assays:

  • Use anti-ubiquitin antibodies (1:300 dilution) to detect TIRAP ubiquitination

  • Investigate how CLIP1 affects the ubiquitination and degradation of TIRAP

  • Compare ubiquitination patterns between different experimental conditions

• Human tissue validation:

  • Examine TFPI2 and CLIP1 expression in human fatty livers

  • Compare expression before and after cold ischemia

  • Correlate expression patterns with clinical outcomes

These methodologies have revealed that HOPE reduces liver injury by inhibiting TFPI2, while CLIP1 can rescue the damaging effects of TFPI2, highlighting a potential therapeutic approach for fatty liver transplantation .

What is the emerging understanding of CLIP1's role in the TFPI2/TIRAP signaling pathway?

Recent research has uncovered a novel role for CLIP1 in inflammatory regulation through the TFPI2/TIRAP pathway:

• Mechanistic pathway:

  • CLIP1 interacts with TFPI2 (tissue factor pathway inhibitor-2)

  • This interaction affects the ubiquitination and subsequent degradation of TIRAP (Toll/interleukin-1 receptor domain-containing adapter protein)

  • TIRAP degradation negatively regulates the TLR4/NF-κB-mediated inflammatory response

  • Specifically, CLIP1 regulates the binding of R24 of the KD1 domain of TFPI2

• Functional significance:

  • In the context of liver transplantation, HOPE (hypothermic oxygenated perfusion) exerts protective effects by inhibiting TFPI2

  • CLIP1 can rescue the damaging effects of TFPI2

  • This pathway plays a crucial role in reducing ischemia-reperfusion injury (IRI) during fatty liver transplantation

• Expression patterns:

  • TFPI2 expression increases following cold ischemia in human fatty livers

  • CLIP1 expression decreases under the same conditions

  • These opposing expression patterns contribute to inflammatory damage

This newly discovered role positions CLIP1 as a potential therapeutic target for modulating inflammatory responses in liver transplantation and potentially other inflammatory conditions.

What are the most promising future research directions for CLIP1 antibody applications?

Based on recent findings, several promising research directions emerge:

• Therapeutic targeting in transplantation:

  • Development of approaches to modulate CLIP1 activity during organ preservation

  • Assessment of CLIP1 as a biomarker for organ quality in transplantation

  • Investigation of the TFPI2/CLIP1/TIRAP pathway as a therapeutic target

• Neurodevelopmental applications:

  • Further characterization of CLIP1's role in intellectual disability

  • Development of CLIP1-based diagnostics for neurodevelopmental disorders

  • Exploration of CLIP1-targeted therapies for cognitive impairments

• Advanced imaging applications:

  • Development of live-cell imaging approaches using fluorescently tagged CLIP1 antibodies

  • Super-resolution microscopy to precisely map CLIP1 dynamics at microtubule plus-ends

  • Correlative light and electron microscopy to understand CLIP1's ultrastructural context

• Domain-specific functional analysis:

  • Development of new antibodies targeting specific functional domains

  • Investigation of domain-specific interactions with binding partners

  • Structure-function analysis of CLIP1 variants associated with disease

• Systems biology approaches:

  • Proteomic analyses of CLIP1 interactomes under different conditions

  • Integration of CLIP1 into broader signaling networks

  • Computational modeling of CLIP1's role in microtubule dynamics and inflammatory signaling

These directions promise to expand our understanding of CLIP1's diverse cellular functions and potentially lead to new diagnostic and therapeutic approaches for conditions ranging from intellectual disability to inflammatory disorders and transplantation medicine .

How can researchers integrate CLIP1 studies with other cytoskeletal research areas?

Integrating CLIP1 research with broader cytoskeletal studies offers opportunities for more comprehensive insights:

• Microtubule-actin crosstalk:

  • Investigate CLIP1's role in linking microtubules to the actin cytoskeleton

  • Study CLIP1's interaction with IQGAP1, which together form a complex that connects actin to microtubules

  • Examine how this crosstalk influences cell migration and neuronal development

• +TIP protein network analysis:

  • Explore interactions between CLIP1 and other +TIP proteins

  • Investigate redundancy and cooperation between CLIP1 and CLIP2

  • Develop comprehensive models of +TIP protein networks and their regulation

• Organelle positioning and transport:

  • Study CLIP1's role in MT-dependent organelle positioning

  • Investigate how CLIP1 influences axonal and dendritic transport

  • Examine connections between transport defects and neurodevelopmental disorders

• Cell division and chromosome segregation:

  • Further characterize CLIP1's contribution to kinetochore-MT attachments during mitosis

  • Investigate potential roles in chromosome segregation defects

  • Explore implications for genomic stability in dividing cells

• Inflammatory signaling and cytoskeletal regulation:

  • Investigate how cytoskeletal dynamics influences inflammatory signaling

  • Explore whether CLIP1's role in TIRAP regulation involves cytoskeletal components

  • Examine how mechanical forces and cytoskeletal rearrangements affect inflammatory responses